

Development of small-molecule asthma drug that inhibits the binding of IL-33 to its receptor



| IMMUNOLOGY | Lead |
|--------------------------|---|
| Product Type | Synthetic small molecule |
| Indication | Asthma (MeSH term) |
| Target | Interleukin 33 (IL-33) |
| MoA(Mechanism of Action) | Azcuris' novel synthetic compound is a first-in-class small-molecule PPI inhibitor that binds to IL-33, thus inhibiting its interaction with ST2 (IL-33 receptor), thereby downregulating the allergic IL-33 signaling pathway. |
| Competitiveness | Small molecule cytokine inhibitors are more competitive than injectable antibodies in terms of ease of administration and cost. In addition, since its MOA is different from that of conventional small-molecule allergy treatment, it is expected to be a blockbuster allergy therapeutics as it can replace or co-administer conventional treatments. |
| Development Stage | Lead |
| Route of Administration | Oral |